Blockbuster obesity drug aims to win $4bn sales for Sanofi-Aventis

French pharmaceuticals group develops treatment for condition at the top of global health agenda

The expected green light from Brussels in the next few weeks would mean that the French giant Sanofi-Aventis could begin marketing the treatment, called rimonabant but branded as Acomplia, later this summer. It is the first of a new generation of drugs set to hit the market in the next few years that could transform obesity, still a small market, into a gold mine for the pharmaceutical industry.

Pfizer, Bayer, Eli Lilly and Merck are developing treatments similar to Acomplia, though they are further behind. Sanofi plans to launch Acomplia first in the UK, Germany, Ireland and Scandinavia.

The timing is auspicious. Governments in Europe and the US have put obesity and its associated conditions, including Type 2 diabetes, at the top of their public health agendas. The Department of Health says that more than half of all British adults - 24 million people - are either overweight or obese. In America, obesity and its complications are estimated to cost the country $70bn (£37bn) annually, according to Scrip Reports.

Gbola Amusa, an analyst with research firm Sanford C Bernstein, said that Acomplia could achieve $4.1bn in annual sales by 2010, in part because it has been shown in clinical trials not only to trim fat but to increase levels of good cholesterol and control diabetes.

"In the blue sky scenario, this could become the world's best- selling drug as the indication is so broad," he said. "It has a path to revenues that we rarely ever see from a pharma product."

The treatment is the first in a new class of drugs called canna- binoid CB-1 blockers, which suppress appetite by blocking the receptor in the brain responsible for hunger pangs, which can be stimulated by marijuana.

The Committee for Medicinal Products for Human Use (CMPH), an advisory group to the European medical regulator EMEA, recommended on 28 April that Acomplia be approved for obese patients, as well as for overweight people with Type 2 diabetes or dyslipidemia, both of which are conditions that governments usually fund. The EC follows CMPH recommendations in nearly all cases.

"We are 99.9 per cent sure of approval," a Sanofi spokesman said.

Only two prescription weight-loss drugs are on the market, and neither has had much success. Abbott's Meridia is an appetite suppressant that produces an artificial sense of being sated, but it also causes hypertension. Roche's Xenical works by blocking the body's ability to absorb fat. However, any fat ingested must be passed out of the body through the bowels, which many patients find uncomfortable.

Neither can be prescribed for any indications beyond weight loss. "It's not being obese that kills you, it's the side-effects that come along with it," said Dr Julian Mercer of the Rowett Institute. "Addressing associated risk factors is a novel aspect."

Approval in America, the world's biggest drugs market, is crucial. The US industry regulator gave an "approvable letter" for Acomplia in February, asking for more time and information before it gave its final decision. Sanofi's head of research and development, Gérard Le Fur, said at the company's annual general meeting in Paris last week that he expects to get US approval by the end of the year.

The indications for which it is approved are also important. Neither Orlistat nor Meridia qualify for reimbursement with US insurers. If the label includes Type 2 diabetes and dyslipidemia, as is expected for Europe, the chances that insurers will pay for it are much greater.

Start your day with The Independent, sign up for daily news emails
ebooksA celebration of British elections
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Ashdown Group: Trainee Consultant - Surrey/ South West London

£22000 per annum + pension,bonus,career progression: Ashdown Group: An establi...

Ashdown Group: Trainee Consultant - Surrey / South West London

£22000 per annum + pension,bonus,career progression: Ashdown Group: An establi...

Recruitment Genius: Claims Administrator

£16000 - £18500 per annum: Recruitment Genius: This is an excellent opportunit...

Recruitment Genius: Senior SEO Executive

£24000 - £28000 per annum: Recruitment Genius: A Senior SEO Executive is requi...

Day In a Page

Fishing for votes with Nigel Farage: The Ukip leader shows how he can work an audience as he casts his line to the disaffected of Grimsby

Fishing is on Nigel Farage's mind

Ukip leader casts a line to the disaffected
Who is bombing whom in the Middle East? It's amazing they don't all hit each other

Who is bombing whom in the Middle East?

Robert Fisk untangles the countries and factions
China's influence on fashion: At the top of the game both creatively and commercially

China's influence on fashion

At the top of the game both creatively and commercially
Lord O’Donnell: Former cabinet secretary on the election and life away from the levers of power

The man known as GOD has a reputation for getting the job done

Lord O'Donnell's three principles of rule
Rainbow shades: It's all bright on the night

Rainbow shades

It's all bright on the night
'It was first time I had ever tasted chocolate. I kept a piece, and when Amsterdam was liberated, I gave it to the first Allied soldier I saw'

Bread from heaven

Dutch survivors thank RAF for World War II drop that saved millions
Britain will be 'run for the wealthy and powerful' if Tories retain power - Labour

How 'the Axe' helped Labour

UK will be 'run for the wealthy and powerful' if Tories retain power
Rare and exclusive video shows the horrific price paid by activists for challenging the rule of jihadist extremists in Syria

The price to be paid for challenging the rule of extremists

A revolution now 'consuming its own children'
Welcome to the world of Megagames

Welcome to the world of Megagames

300 players take part in Watch the Skies! board game in London
'Nymphomaniac' actress reveals what it was really like to star in one of the most explicit films ever

Charlotte Gainsbourg on 'Nymphomaniac'

Starring in one of the most explicit films ever
Robert Fisk in Abu Dhabi: The Emirates' out-of-sight migrant workers helping to build the dream projects of its rulers

Robert Fisk in Abu Dhabi

The Emirates' out-of-sight migrant workers helping to build the dream projects of its rulers
Vince Cable interview: Charging fees for employment tribunals was 'a very bad move'

Vince Cable exclusive interview

Charging fees for employment tribunals was 'a very bad move'
Iwan Rheon interview: Game of Thrones star returns to his Welsh roots to record debut album

Iwan Rheon is returning to his Welsh roots

Rheon is best known for his role as the Bastard of Bolton. It's gruelling playing a sadistic torturer, he tells Craig McLean, but it hasn't stopped him recording an album of Welsh psychedelia
Morne Hardenberg interview: Cameraman for BBC's upcoming show Shark on filming the ocean's most dangerous predator

It's time for my close-up

Meet the man who films great whites for a living
Increasing numbers of homeless people in America keep their mobile phones on the streets

Homeless people keep mobile phones

A homeless person with a smartphone is a common sight in the US. And that's creating a network where the 'hobo' community can share information - and fight stigma - like never before